After hours:
| Previous Close | 1.2000 |
| Open | 1.2000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 1.2000 - 1.2800 |
| 52 Week Range | 0.7340 - 2.4000 |
| Volume | |
| Avg. Volume | 129,601 |
| Market Cap | 28.236M |
| Beta (5Y Monthly) | -2.82 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.8400 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 8.75 |
GlobeNewswireFemasys to Exhibit at ASRM 2024 and Participate in the Congress’ KEEPR Education Program
Company’s VP of Education and Global Training Named Chairman of ASRM Corporate Member CouncilATLANTA, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that the Company will be exhibiting at the American Society of Reproductive Medicine’s (ASRM) 2024 Scientific Congress and Expo,
- GlobeNewswire
Femasys to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
ATLANTA, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Femasys, Inc., (Nasdaq: FEMY), a leading biomedical company focused on addressing significant unmet needs of women worldwide with a broad portfolio of in-office, accessible, and innovative therapeutic and diagnostic products, announces that Kathy Lee-Sepsick, Founder, President, and CEO, will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit with Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Research at
